220 related articles for article (PubMed ID: 11019857)
21. Inhibition of toxicity in the beta-amyloid peptide fragment beta -(25-35) using N-methylated derivatives: a general strategy to prevent amyloid formation.
Hughes E; Burke RM; Doig AJ
J Biol Chem; 2000 Aug; 275(33):25109-15. PubMed ID: 10825171
[TBL] [Abstract][Full Text] [Related]
22. Beta-amyloid protein aggregation.
Etienne MA; Edwin NJ; Aucoin JP; Russo PS; McCarley RL; Hammer RP
Methods Mol Biol; 2007; 386():203-25. PubMed ID: 18604947
[TBL] [Abstract][Full Text] [Related]
23. Assemblages of prion fragments: novel model systems for understanding amyloid toxicity.
Satheeshkumar KS; Murali J; Jayakumar R
J Struct Biol; 2004 Nov; 148(2):176-93. PubMed ID: 15477098
[TBL] [Abstract][Full Text] [Related]
24. Histidine residues underlie Congo red binding to A beta analogs.
Inouye H; Nguyen JT; Fraser PE; Shinchuk LM; Packard AB; Kirschner DA
Amyloid; 2000 Sep; 7(3):179-88. PubMed ID: 11019858
[TBL] [Abstract][Full Text] [Related]
25. The influence of the central region containing residues 19-25 on the aggregation properties and secondary structure of Alzheimer's beta-amyloid peptide.
El-Agnaf OM; Guthrie DJ; Walsh DM; Irvine GB
Eur J Biochem; 1998 Sep; 256(3):560-9. PubMed ID: 9780232
[TBL] [Abstract][Full Text] [Related]
26. Aggregation state and neurotoxic properties of Alzheimer beta-amyloid peptide.
Howlett DR; Jennings KH; Lee DC; Clark MS; Brown F; Wetzel R; Wood SJ; Camilleri P; Roberts GW
Neurodegeneration; 1995 Mar; 4(1):23-32. PubMed ID: 7600183
[TBL] [Abstract][Full Text] [Related]
27. Fibrillogenesis of synthetic amyloid-beta peptides is dependent on their initial secondary structure.
Soto C; Castaño EM; Kumar RA; Beavis RC; Frangione B
Neurosci Lett; 1995 Nov; 200(2):105-8. PubMed ID: 8614555
[TBL] [Abstract][Full Text] [Related]
28. pH-dependent amyloid and protofibril formation by the ABri peptide of familial British dementia.
Srinivasan R; Jones EM; Liu K; Ghiso J; Marchant RE; Zagorski MG
J Mol Biol; 2003 Nov; 333(5):1003-23. PubMed ID: 14583196
[TBL] [Abstract][Full Text] [Related]
29. Amyloid-induced aggregation and precipitation of soluble proteins: an electrostatic contribution of the Alzheimer's beta(25-35) amyloid fibril.
Konno T
Biochemistry; 2001 Feb; 40(7):2148-54. PubMed ID: 11329283
[TBL] [Abstract][Full Text] [Related]
30. Interactions of Alzheimer amyloid-beta peptides with glycosaminoglycans effects on fibril nucleation and growth.
McLaurin J; Franklin T; Zhang X; Deng J; Fraser PE
Eur J Biochem; 1999 Dec; 266(3):1101-10. PubMed ID: 10583407
[TBL] [Abstract][Full Text] [Related]
31. Fibril formation by primate, rodent, and Dutch-hemorrhagic analogues of Alzheimer amyloid beta-protein.
Fraser PE; Nguyen JT; Inouye H; Surewicz WK; Selkoe DJ; Podlisny MB; Kirschner DA
Biochemistry; 1992 Nov; 31(44):10716-23. PubMed ID: 1420187
[TBL] [Abstract][Full Text] [Related]
32. Study of the conformational transition of A beta(1-42) using D-amino acid replacement analogues.
Janek K; Rothemund S; Gast K; Beyermann M; Zipper J; Fabian H; Bienert M; Krause E
Biochemistry; 2001 May; 40(18):5457-63. PubMed ID: 11331010
[TBL] [Abstract][Full Text] [Related]
33. Self-propagating, molecular-level polymorphism in Alzheimer's beta-amyloid fibrils.
Petkova AT; Leapman RD; Guo Z; Yau WM; Mattson MP; Tycko R
Science; 2005 Jan; 307(5707):262-5. PubMed ID: 15653506
[TBL] [Abstract][Full Text] [Related]
34. Influence of residue 22 on the folding, aggregation profile, and toxicity of the Alzheimer's amyloid beta peptide.
Perálvarez-Marín A; Mateos L; Zhang C; Singh S; Cedazo-Mínguez A; Visa N; Morozova-Roche L; Gräslund A; Barth A
Biophys J; 2009 Jul; 97(1):277-85. PubMed ID: 19580765
[TBL] [Abstract][Full Text] [Related]
35. Amyloid fibril formation requires a chemically discriminating nucleation event: studies of an amyloidogenic sequence from the bacterial protein OsmB.
Jarrett JT; Lansbury PT
Biochemistry; 1992 Dec; 31(49):12345-52. PubMed ID: 1463722
[TBL] [Abstract][Full Text] [Related]
36. Structural studies of soluble oligomers of the Alzheimer beta-amyloid peptide.
Huang TH; Yang DS; Plaskos NP; Go S; Yip CM; Fraser PE; Chakrabartty A
J Mol Biol; 2000 Mar; 297(1):73-87. PubMed ID: 10704308
[TBL] [Abstract][Full Text] [Related]
37. Analysis of amylin cleavage products provides new insights into the amyloidogenic region of human amylin.
Nilsson MR; Raleigh DP
J Mol Biol; 1999 Dec; 294(5):1375-85. PubMed ID: 10600392
[TBL] [Abstract][Full Text] [Related]
38. Beta-amyloid neurotoxicity requires fibril formation and is inhibited by congo red.
Lorenzo A; Yankner BA
Proc Natl Acad Sci U S A; 1994 Dec; 91(25):12243-7. PubMed ID: 7991613
[TBL] [Abstract][Full Text] [Related]
39. ApoE protects cortical neurones against neurotoxicity induced by the non-fibrillar C-terminal domain of the amyloid-beta peptide.
Drouet B; Fifre A; Pinçon-Raymond M; Vandekerckhove J; Rosseneu M; Guéant JL; Chambaz J; Pillot T
J Neurochem; 2001 Jan; 76(1):117-27. PubMed ID: 11145984
[TBL] [Abstract][Full Text] [Related]
40. The extreme N-terminal region of human apolipoprotein A-I has a strong propensity to form amyloid fibrils.
Adachi E; Kosaka A; Tsuji K; Mizuguchi C; Kawashima H; Shigenaga A; Nagao K; Akaji K; Otaka A; Saito H
FEBS Lett; 2014 Jan; 588(3):389-94. PubMed ID: 24316228
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
